Omnicell (NASDAQ:OMCL) Upgraded at Zacks Research

by · The Cerbat Gem

Zacks Research upgraded shares of Omnicell (NASDAQ:OMCL – Free Report) from a hold rating to a strong-buy rating in a research note issued to investors on Wednesday,Zacks reports.

Several other analysts also recently weighed in on OMCL. Piper Sandler reiterated an “overweight” rating and set a $45.00 price target (down from $55.00) on shares of Omnicell in a research note on Monday, August 3rd. KeyCorp restated an “overweight” rating on shares of Omnicell in a research note on Monday, August 24th. Wells Fargo & Company reduced their price objective on Omnicell from $55.00 to $50.00 and set an “overweight” rating for the company in a research note on Friday, July 31st. Finally, Weiss Ratings raised Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 18th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $57.86.

Check Out Our Latest Stock Report on OMCL

Omnicell Stock Performance

NASDAQ:OMCL traded down $0.69 during trading hours on Wednesday, hitting $37.34. 562,785 shares of the company were exchanged, compared to its average volume of 568,010. The stock has a market capitalization of $1.70 billion, a price-to-earnings ratio of 38.90, a PEG ratio of 1.00 and a beta of 0.88. Omnicell has a 52-week low of $31.75 and a 52-week high of $55.00. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.65 and a quick ratio of 1.45. The company’s 50 day moving average price is $34.93 and its 200-day moving average price is $38.78.

Omnicell (NASDAQ:OMCL – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The company reported $0.58 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.42 by $0.16. Omnicell had a net margin of 3.59% and a return on equity of 5.69%. The business had revenue of $307.85 million during the quarter, compared to analysts’ expectations of $304.44 million. During the same quarter last year, the company posted $0.51 earnings per share. The business’s quarterly revenue was down .9% on a year-over-year basis. As a group, research analysts forecast that Omnicell will post 1.64 earnings per share for the current year.

Institutional Trading of Omnicell

Hedge funds have recently modified their holdings of the stock. Nykredit A S acquired a new position in Omnicell in the second quarter valued at approximately $26,000. Versant Capital Management Inc grew its stake in shares of Omnicell by 38.7% during the 2nd quarter. Versant Capital Management Inc now owns 1,053 shares of the company’s stock worth $44,000 after purchasing an additional 294 shares during the period. Fulcrum Asset Management LLP grew its stake in shares of Omnicell by 2,536.4% during the 3rd quarter. Fulcrum Asset Management LLP now owns 1,160 shares of the company’s stock worth $40,000 after purchasing an additional 1,116 shares during the period. Northwestern Mutual Wealth Management Co. purchased a new position in shares of Omnicell during the 2nd quarter valued at approximately $105,000. Finally, Nisa Investment Advisors LLC increased its holdings in shares of Omnicell by 21.9% during the 3rd quarter. Nisa Investment Advisors LLC now owns 2,613 shares of the company’s stock valued at $89,000 after purchasing an additional 469 shares in the last quarter. Hedge funds and other institutional investors own 97.70% of the company’s stock.

Omnicell News Summary

Here are the key news stories impacting Omnicell this week:

  • Positive Sentiment: Zacks Research upgraded Omnicell from “hold” to “strong-buy,” adding to the bullish analyst-rating momentum. Tickerreport article
  • Positive Sentiment: Zacks cited solid earnings-estimate revisions as a reason OMCL may continue moving higher in the near term. Zacks earnings-estimate revisions article
  • Positive Sentiment: OMCL was added to Zacks’ Rank #1 (Strong Buy) lists for momentum and value stocks, reinforcing the favorable assessment. Zacks momentum stocks article Zacks value stocks article
  • Neutral Sentiment: A Zacks article noted that analysts’ consensus target implies substantial potential upside, but cautioned that price targets alone have limited predictive value; it also pointed to estimate revisions as a more encouraging signal. Zacks analyst price-target article

About Omnicell

(Get Free Report)

Omnicell, Inc develops medication management and adherence solutions for health care providers, pharmacies and patients. Its technologies are designed to help automate medication dispensing, improve inventory control, support clinical workflows and enhance medication access and adherence across the care continuum.

The company’s product portfolio includes automated dispensing cabinets for hospitals and health systems, central pharmacy and intravenous compounding automation, medication packaging and adherence solutions, and software for analytics, inventory management and pharmacy operations.

Further Reading